A risk stratification guide could help clinicians select the optimal intensity of chemotherapy for patients with acute myeloid leukemia (AML).
The guide was developed as part of a study that identified a number of clinical variables that could predict risk for early mortality in new AML patients undergoing intensive chemotherapy (Am J Hematol 2022;97[1]:68-78).
“The proposed early mortality risk classification may help guide the need for, and [risks/benefits] of, intensive versus low